Molecular detection of minimal residual cancer in surgical margins of head and neck cancer patients

被引:12
作者
Graveland, A. Peggy
de Maaker, Michiel
Braakhuis, Boudewijn J. M.
de Bree, Remco
Eerenstein, Simone E. J.
Bloemena, Elisabeth [2 ,3 ]
Leemans, C. Rene
Brakenhoff, Ruud H. [1 ]
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Otolaryngol Head & Neck Surg, Tumor Biol Sect, NL-1007 MB Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1007 MB Amsterdam, Netherlands
[3] Acad Ctr Dent Amsterdam, NL-1066 EA Amsterdam, Netherlands
关键词
Head and neck cancer; hLy-6D; minimal residual cancer; molecular diagnosis; qRT-PCR; surgical margin; SQUAMOUS-CELL CARCINOMA; POLYMERASE-CHAIN-REACTION; LYMPH-NODES; BONE-MARROW; CLINICAL-SIGNIFICANCE; EPITHELIAL DYSPLASIA; PROGNOSTIC FACTOR; LOCAL RECURRENCE; PCR DETECTION; TUMOR-CELLS;
D O I
10.3233/CLO-2009-0474
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A great disappointment in head and neck cancer surgery is that 10-30% of head and neck squamous cell carcinoma (HNSCC) patients develop local recurrences despite histopathologically tumor-free surgical margins. These recurrences result from either minimal residual cancer (MRC) or preneoplastic lesions that remain behind after tumor resection. Distinguishing MRC from preneoplasic lesions is important to tailor postoperative radiotherapy more adequately. Here we investigated the suitability of quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) using human Ly-6D (hLy-6D) transcripts as molecular marker to detect MRC in surgical margins. Submucosal samples of deep surgical margins were collected from 18 non-cancer control patients and 67 HNSCC patients of whom eight had tumor-positive surgical margins. The samples were analyzed with hLy-6D qRT-PCR, and the data were analyzed in relation to the clinicohistological parameters. A significant difference was shown between the group of patients with histopathological tumor-positive surgical margins and the non-cancer control group (p < 0.001), and the group of patients with histopathological tumor-free surgical margins (p = 0.001). This study shows a novel approach for molecular analysis of deep surgical margins in head and neck cancer surgery. The preliminary data of this approach for detection of MRC in deep margins of HNSCC patients are promising.
引用
收藏
页码:317 / 328
页数:12
相关论文
共 33 条
[1]   Surgical excision margins: A pathologist's perspective [J].
Batsakis, JG .
ADVANCES IN ANATOMIC PATHOLOGY, 1999, 6 (03) :140-148
[2]   QUALITY-OF-LIFE IN PATIENTS TREATED FOR HEAD AND NECK-CANCER - A FOLLOW-UP-STUDY 7 TO 11 YEARS AFTER RADIOTHERAPY [J].
BJORDAL, K ;
KAASA, S ;
MASTEKAASA, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 28 (04) :847-856
[3]  
Braakhuis BJM, 2003, CANCER RES, V63, P1727
[4]  
Brakenhoff RH, 1999, CLIN CANCER RES, V5, P725
[5]   MOLECULAR ASSESSMENT OF HISTOPATHOLOGICAL STAGING IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK [J].
BRENNAN, JA ;
MAO, L ;
HRUBAN, RH ;
BOYLE, JO ;
EBY, YJ ;
KOCH, WM ;
GOODMAN, SN ;
SIDRANSKY, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (07) :429-435
[6]   Clinical significance of micrometastatic cells detected by E48 (Ly-6D) reverse transcription-polymerase chain reaction in bone marrow of head and neck cancer patients [J].
Colnot, DR ;
Nieuwenhuis, EJC ;
Kuik, DJ ;
Leemans, CR ;
Dijkstra, J ;
Snow, GB ;
van Dongen, GAMS ;
Brakenhoff, RH .
CLINICAL CANCER RESEARCH, 2004, 10 (23) :7827-7833
[7]   Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma [J].
Dalen, AGD ;
van Dongen, GAMS ;
Smeets, SJ ;
Nieuwenhuis, EJC ;
Walsum, MSV ;
Snow, GB ;
Brakenhoff, RH .
INTERNATIONAL JOURNAL OF CANCER, 2003, 103 (06) :768-774
[8]   Molecular staging of cervical lymph nodes in squamous cell carcinoma of the head and neck [J].
Ferris, RL ;
Xi, LQ ;
Raja, S ;
Hunt, JL ;
Wang, J ;
Gooding, WE ;
Kelly, L ;
Ching, J ;
Luketich, JD ;
Godfrey, TE .
CANCER RESEARCH, 2005, 65 (06) :2147-2156
[9]  
LEEMANS CR, 1994, CANCER-AM CANCER SOC, V73, P187, DOI 10.1002/1097-0142(19940101)73:1<187::AID-CNCR2820730132>3.0.CO
[10]  
2-J